A phase 1 and pharmacokinetic study of enzastaurin in pediatric patients with refractory primary central nervous system tumors: a pediatric brain tumor consortium study

Randomized, Phase II, Placebo-Controlled, Double-Blind Study With and Without Enzastaurin in Combination With Paclitaxel and Carboplatin As First-Line Treatment Followed by Maintenance Treatment in Advanced Ovarian Cancer

(2013) Ignace B. Vergote et al.   JOURNAL OF CLINICAL ONCOLOGY

Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation

(2013) W. Wick et al.   NEURO-ONCOLOGY

Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokinetics

(2012) Nwabundo Nwankwo et al.   INVESTIGATIONAL NEW DRUGS

A placebo-controlled, randomized phase II study of maintenance enzastaurin following whole brain radiation therapy in the treatment of brain metastases from lung cancer

(2012) Bjørn H. Grønberg et al.   LUNG CANCER

A phase I study of LY317615 (enzastaurin) and temozolomide in patients with gliomas (EORTC trial 26054)

(2012) R. Rampling et al.   NEURO-ONCOLOGY

A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas

(2011) Teri N. Kreisl et al.   NEURO-ONCOLOGY

Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma

(2011) N. Butowski et al.   NEURO-ONCOLOGY

Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy

(2010) Mark Clemons et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase I dose escalation and pharmacokinetic study of oral enzastaurin (LY317615) in advanced solid tumors

(2010) Toru Mukohara et al.   CANCER SCIENCE

Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma

(2010) Wolfgang Wick et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II, Double-Blinded, Randomized Study of Enzastaurin Plus Pemetrexed as Second-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer

(2010) Alberto Chiappori et al.   Journal of Thoracic Oncology

Randomized, Double-Blinded, Multicenter, Phase II Study of Pemetrexed, Carboplatin, and Bevacizumab with Enzastaurin or Placebo in Chemonaïve Patients with Stage IIIB/IV Non-small Cell Lung Cancer: Hoosier Oncology Group LUN06-116

(2010) Erin M. Casey et al.   Journal of Thoracic Oncology

Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: A phase I study

(2010) N. Butowski et al.   NEURO-ONCOLOGY

Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer

(2009) A.-R. Hanauske et al.   ANNALS OF ONCOLOGY

Long-term follow-up of chemonaive patients with asymptomatic metastatic colorectal cancer treated with enzastaurin in a window of opportunity phase II study

(2009) B. Glimelius et al.   ANNALS OF ONCOLOGY

A window of opportunity phase II study of enzastaurin in chemonaive patients with asymptomatic metastatic colorectal cancer

(2009) B. Glimelius et al.   ANNALS OF ONCOLOGY

A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors

(2009) D. Ross Camidge et al.   ANTI-CANCER DRUGS

Synergistic effect of Sorafenib and Sunitinib with Enzastaurin, a selective protein kinase C inhibitor in renal cell carcinoma cell lines

(2009) Ursula Maria Vogl et al.   CANCER LETTERS

A Phase I Trial of Enzastaurin in Patients with Recurrent Gliomas

(2009) T. N. Kreisl et al.   CLINICAL CANCER RESEARCH

Enzastaurin (LY317615), a Protein Kinase C Beta Selective Inhibitor, Enhances Antiangiogenic Effect of Radiation

(2009) Christopher D. Willey et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane containing regimen

(2009) Lida Mina et al.   INVESTIGATIONAL NEW DRUGS

Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: Results of a Phase II, randomized, noncomparative study

(2009) Donald A. Richards et al.   INVESTIGATIONAL NEW DRUGS

Continual Reassessment Method vs. Traditional Empirically Based Design: Modifications Motivated by Phase I Trials in Pediatric Oncology by the Pediatric Brain Tumor Consortium

(2009) Arzu Onar et al.   Journal of Biopharmaceutical Statistics

Design of Phase II Cancer Trials for Evaluation of Cytostatic/Cytotoxic Agents

(2009) Masha Kocherginsky et al.   Journal of Biopharmaceutical Statistics

Late Effects of Therapy for Pediatric Brain Tumor Survivors

(2009) Christopher D. Turner et al.   JOURNAL OF CHILD NEUROLOGY

Enzastaurin shows preclinical antitumor activity against human transitional cell carcinoma and enhances the activity of gemcitabine

(2009) W. Jian et al.   MOLECULAR CANCER THERAPEUTICS

Enzastaurin renders MCF-7 breast cancer cells sensitive to radiation through reversal of radiation-induced activation of protein kinase C

(2008) Piotr Jasinski et al.   EUROPEAN JOURNAL OF CANCER

A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma

(2007) F. Morschhauser et al.   ANNALS OF ONCOLOGY